Does Avelumab Cause Merkel Cell Carcinoma? A Comprehensive Review

From General Health Awareness to Occupational Risk Assessment

The legacy context of general health and science information has long emphasized the importance of understanding how lifestyle factors, including substance use, can influence well-being. Discussions around alcohol consumption during periods of stress, such as the COVID-19 pandemic, have highlighted the need for individuals to maintain awareness of their habits and their potential physical and psychological impacts. This foundational perspective underscores a broader principle: any substance introduced into the body warrants careful consideration of its effects, particularly when exposure is sustained or occurs in specific populations. Transitioning from this general health awareness to a more focused occupational concern, we now consider the implications of therapeutic agents used in controlled medical settings. In mass production environments, workers may encounter pharmaceutical compounds during manufacturing, handling, or administration. One such agent is Avelumab, a monoclonal antibody employed in oncology. The central query here is whether occupational exposure to Avelumab could be associated with the development of Merkel Cell Carcinoma. This pivot moves the discussion from broad lifestyle-related health maintenance to a precise, workplace-specific risk assessment, examining the potential for causation between a biologic drug and a rare skin cancer.

Pharmacology and Clinical Context of Avelumab

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The question of whether avelumab causes Merkel cell carcinoma requires careful examination of the drug's pharmacology, clinical evidence, and mechanistic pathways. Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Its incidence is increasing, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab was specifically approved for metastatic MCC based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). This indicates that avelumab is used as a treatment for existing MCC, not as a causative agent.

Mechanistic Evidence and Risk Assessment

Pharmacologically, avelumab blocks PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. However, checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This demonstrates that avelumab can trigger immune-mediated reactions but does not suggest it causes MCC. Mechanistic pathways linking avelumab to MCC causation are not supported by the evidence. Instead, the literature consistently describes avelumab as a therapeutic agent for MCC. For instance, avelumab is the first therapeutic agent specifically approved for metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). In avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab has shown responses, with three out of five patients in one study responding according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). These data reinforce that avelumab is used to treat MCC, not cause it.

Risk Anchors and Causation Considerations

Regarding risk anchors, the adequacy of warnings about avelumab and MCC is addressed by the drug's approved indication. Avelumab is indicated for the treatment of metastatic MCC, meaning patients are already diagnosed with the disease before receiving the drug. The prescribing information would include warnings about immune-related adverse events, but not about causing MCC, as that is not a known effect. For affected patients, causation-related considerations are straightforward: avelumab is not a cause of MCC. The timeline between exposure and documented harm is irrelevant for causation because the drug is administered after MCC diagnosis. In the JAVELIN Merkel 200 trial, patients had chemotherapy-refractory metastatic MCC before receiving avelumab, so any harm from the drug would be related to adverse events, not the development of MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). In summary, the evidence does not support a causal link between avelumab and Merkel cell carcinoma. Avelumab is an approved treatment for metastatic MCC, and its use is associated with immune-related adverse events, but not with causing the disease. The drug's pharmacology, clinical trial data, and mechanistic pathways all indicate it is a therapeutic agent for MCC, not a trigger. Patients and clinicians should be aware of potential immune-related adverse events, but there is no evidence that avelumab causes Merkel cell carcinoma.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel cell carcinoma?

No, there is no evidence that Avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor approved for the treatment of metastatic Merkel cell carcinoma, meaning it is used to treat the disease, not cause it. Clinical trials and pharmacological data consistently show that Avelumab targets PD-L1 to enhance immune response against cancer cells, and its use is associated with immune-related adverse events, but not with the development of MCC.

What is the relationship between Avelumab and Merkel cell carcinoma?

Avelumab is a therapeutic agent for Merkel cell carcinoma. It was approved based on the JAVELIN Merkel 200 trial, which demonstrated objective responses in patients with chemotherapy-refractory metastatic MCC. The drug is administered after diagnosis, so there is no causal link from Avelumab to MCC. Instead, Avelumab helps treat existing MCC by blocking PD-L1 and activating the immune system against cancer cells.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.